tara

tara
LA Mayor's Office Acknowledges the NDF's Advocacy with GNEM

Tuesday, July 31, 2012

A Rudimentary Explanation into Mutations on the GNE Gene; Amino Acids, Proteins, Enzymes, Exons and Introns


 
(This is a review from one of my previous posts just to have a little background into understanding my new post).

"GNE's official name is "glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase." The Gne gene is called a "bi-functional" enzyme which gives instructions to make an enzyme in the body. This enzyme sends messages between cells and tissues to carry out certain functions...
At a point in this production cycle we get a substance (substrate) called ManNAc which is changed to to ManNAc-6 (this means a phosphate molecule is added), later along this cycle it then changes to sialic acid. Because there is less sialic acid available for the muscles they get weaker and we get HIBM."

Hereditary Inclusion Body Myopathy (HIBM) is known by  many other names such as Nonaka Myopathy, Distal Myopathy with Rimmed Vacuoles (DMRV), IBM2, GNE Myopathy and some others.  Researchers have found  over 60 different mutuations in the GNE gene which result in HIBM.  They may continue to find more mutuations as patients get tested. 

There are clusters of mutations within ethnic groups and we know that HIBM is more prevalent within the Persian Jewish community.  There are other  groups found  in Japan, India and the Middle East.  Most of these groups carry different mutations. In my family, researchers found a "novel" (new) mutation that was not previously mentioned in medical journals.

As with any disease and especially with hereditary diseases it is important to get genetic counseling.  I know most of my friends and family with an HIBM diagnosis have  had counseling with geneticists or doctors.  In my case, I have 2 different mutations, one inherited from each of my parent and both of my  mutations occur on the kinase domain of the GNE gene.

 On the GNE gene there are  two protein sections which are known as domains.  One is called the kinase domain and the other is epimerase. Mutations on the GNE gene occur either on the kinase domain and or the epimerase domain. It is reported in medical literature that the kinase domain consists 722 amino acids and the Epimerase has 753 amino acids.

My mutations were explained to me by a doctor this way:
Imagine the GNE gene like a ruler with 12 inches and for each inch there is a line dividing the ruler in 12 parts which are called "exons". In between the exons are introns. The exons are in charge for the coding of the amino acids in the protein. One of my mutations occurs between th 9th and 10th exon and the other occurs on the 12th exon.  ( Consult your GNE sequencing  report and you may see some information similiar to this).

_____________________________________________________________________________
1           2           3            4           5           6           7           8           9           10           11            12

Epimerase domain                                                                Kinase domain
I have not encountered any medical articles where it mentions whether ManNAc or Sialic Acid would be more effective for a kinase or epimerase mutation


Some terminology that are used  when we talk about HIBM

Exons are segments of dna that carry the codes for  proteins.
Amino acids are small parts of a protein  that are linked together to form a  protein.
Protein are complex organic compounds that are made up of simpler compounds that attach to each and are called amino acids
 Enzymes are  proteins - GNE is a Bi-functional enzyme =  It carries out a 2 step process in the making of sialic acid.  Enzymes can speed up chemical reactions in the body, change a protein or slow down a process.

*Note: I have read and compiled the above information from these sites listed below.  I have also used my GNE sequencing information.

http://glycob.oxfordjournals.org/content/20/3/322.full

Friday, July 20, 2012

Out and About at UCLA Campus



                     (Information for patients travelling to UCLA)
UCLA  campus is nestled in  beautiful Westwood area of Los Angeles. The streets are not as busy and chaotic as Los Angeles proper. The campus was founded in 1919 and stretches over 419 acres. There are some beautiful  sites and I like to observe some of the  architecturally quaint and interesting buildings on the campus and nearby. 
                  When I travel to UCLA, I usually stay at the Tiverton House.  It has about 100 rooms for patients and family visiting the Medical Center.  The Tiverton's staff are very hospitable, helpful, and friendly.  They have handicapped accessible rooms, and an accessible shuttle to take patients to the Medical Center. Request  for the shuttle needs to be made 30 minutes prior to  appointment time.  There is a library, a business room with 2 public computers/printer, a very nice sitting room and some outdoor sitting areas.  They offer free newspapers, breakfast and have a kitchen for those wishing to prepare their meals. There is also a refrigerator and shower chair in the accessible rooms.
                 Almost all nearby business are accessible and they are in close vicinity to  Tiverton House.  There are nearby restaurants that offer room delivery and a big grocery store less than half a block from the Tiverton House.    I love the food at "Native Cafe" which is close by and serves   delicious vegan food.  There is a cafe opposite the Medical Center and may be little  challenging for someone with HIBM to walk to. I  use my battery operated wheelchair  to go to my appointments, restaurants,  and tour around the campus.  Somehow it allows me to maintain some semblance of independence.
                  Good luck to you all going to the Medical Center. Please add to this blog if you have additional information that may help others.
Link to the Tiverton House.http://tivertonhouse.ucla.edu/


Ultragenyx Announces Phase 2 Trial of Sialic Acid on Their Site

Ultragenyx has posted on their web site the initiation of  phase 2 trial using sialic acid extended release tablets. This announcement has been on clinicaltrials.gov site for a while now.
Please refer to the link.  All four centers are recruiting patients at this time.

http://www.ultragenyx.com/index.php?ht=action/GetDocumentAction/i/5045

Friday, July 13, 2012

New Zealand Pharmaceuticals collaborating with the National Institutes of Health on the ManNAc trial - Dex-M74

There has been  quite alot of news on research progress this week with HIBM.  I feel absolutely forntunate to  have met Dr. Gahl and the exceptional staff/researchers at NIH and to see the progress with this study.  For those who are/were involved with the Natural History Study of HIBM, well here is good news. As always, I have attached the link at the bottom of this posting.

New Drug Development Partnership
National Human Genome Research Institute (NHGRI) (Bethesda, MD; www.genome.gov) and New Zealand Pharmaceuticals Ltd (NZP) (Palmerston North, New Zealand; www.nzp.co.nz) have partnered on a drug development project. The goal is to reduce or halt the progression of a rare disorder, Hereditary Inclusion Body Myopathy (HIBM) by treating affected patients with a small molecule therapeutic drug. HIBM primarily affects distal muscle tissue, and due to dramatically decreased muscle strength, most HIBM patients must use a wheelchair by the time they are in their 30s. NZP has licensed NHGRI’s patent portfolio related to treating HIBM and other muscle wasting diseases, as well as kidney diseases related to hyposialylation, with a monosaccharide N-Acetyl-D-mannosamine (ManNAc), also known as DEX-M74. DEX-M74 is one of the first molecules to enter development in the Therapeutics for Rare and Neglected Diseases (TRND) program (http://nctt.nih.gov/trnd) at the National Institutes of Health (NIH). NZP and TRND are currently collaborating to complete needed pre-clinical studies for treating HIBM with DEX-M74 - these studies will be the basis of an investigational new drug application (IND) to be submitted to the Food and Drug Administration (FDA). Once the IND goes into effect, a phase I/II clinical trial is scheduled to begin at the NIH Clinical Center. That study will be led by HIBM expert and NHGRI Clinical Director, Dr. William Gahl, M.D., Ph.D.

Updated Instructions on how to Follow my Blog

I have finally figure out how my friends, family and others can follow my blog.  Thanks to all who have been following my postings.
Here are the steps:
1.  Go to my blog site and scroll to the bottom of the page
2. You will see "newer posts", "home", "older posts"
3.  Click "older posts" and scroll back to the bottom of the page
4.  You should see an option for  "join" this site, 
5.  A window opens up, and asks you to sign in using your yahoo, google, twitter account.
4. You could choose to follow publicly or privately

 I know some of my friends have had problems on my site,  please email me if you have any problems or suggestions.

I have attached a link from google with the instructions for following blogs
http://support.google.com/blogger/bin/answer.py?hl=en&answer=104226

Thursday, July 12, 2012

New Gene Transfer shows Promise for Limb Girdle and other Muscular Dystrophies

When I was misdiagnosed and placed in the Limb Girdle muscular dystrophy category, I was hoping that the gene therapy the researchers were trying  at the time would be successfull.  This article just released shows how far gene therapy has come and I think  there is great hope for people with HIBM.  I have attached the link of the complete article.

"The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies".


http://www.labspaces.net/121546/New_gene_transfer_strategy_shows_promise_for_limb_girdle_and_other_muscular_dystrophies

Sunday, July 8, 2012

Clinical Trials for Sialic Acid by Ultragenyx, and ManNAc by the NIH

The  clinical trial for sialic acid phase 2 is currently recruiting at all 3 sites in the United States and one site in Jerusalem, Israel.  I  have attached the link at the bottom of this blog.  Please send me a comment if you are unable to access the link.

In addition, the National Institutes of Health has  just listed  a clinical trial for phase one of ManNAc.  They are not yet recruiting  for this phase.  The Natural History study continues and they are still recruiting patients to participate in the study.   Likewise, I have attached the links.

On a personal note. I am pleased to state that I have been screened and accepted into the clinical trial  for phase 2 of sialic acid.  I   have been going to the UCLA site in Southern California for the study.

Sialic Acid trial phase 2:
http://clinicaltrials.gov/ct2/show/NCT01517880?term=hibm&rank=5

ManNAc announcement for phase 1:
http://clinicaltrials.gov/ct2/show/NCT01634750?term=hibm&rank=1

Natural History Study conducted by the National Institutes of Health
http://clinicaltrials.gov/ct2/show/NCT01417533?term=hibm&rank=3

Wednesday, July 4, 2012

Dr. D. Darvish and Dr. B. Darvish Talks About Their Research and Experience with HIBM


This is discussion by two doctors who have HIBM.  They have dedicated their lives and resources to finding a cure for HIBM. It's quite a touching, poignant and heartwarming story. (For those who are unable to access this link, please let me know).

http://www.laweekly.com/2012-07-05/news/HIBM-rare-diseases-bobby-darvish-daniel-darvish/4/